NEWS

Feburary 1st, 2024

Adovate Completes Key Obligations Related to Acquisition of Its Adenosine Drug Development Platform  

Security interests & anti-dilution encumbrances on assets settled. Charlottesville, VA – Feb 1, 2024 – Adovate, LLC (“Adovate” or “the Company”), a pharma firm focusing on adenosine receptor drugs for major diseases, updates acquisition of adenosine drug platform & assets

Read More

January 09, 2024

Adovate, Awarded $800,000 by Virginia Catalyst for Phase 2 Clinical Trial of ADO-5030

 ADO-5030 has the potential to transform the treatment of asthma. Charlottesville, VA – January 9, 2024 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing drug candidates targeting the adenosine receptors, today announced its receipt of a

Read More

November 15, 2023

Adovate Announces Patent Issuance in the United States for its Next Generation Adenosine 2B Receptor Antagonists 

Patent covers lead drug candidate, ADO-5030, for asthma. Charlottesville, VA – November 15, 2023 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing novel drugs targeting adenosine receptors involved in major diseases, announces that the

Read More